Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Psychometric properties of the engaged living scale (ELS) Spanish version in a large sample of Spanish pilgrims

  • Navarrete, J.
  • Colomer-Carbonell, A.
  • Sanabria-Mazo, J. P.
  • Luciano, J. V.
  • Soler, J.
  • García-Campayo, J.
  • Demarzo, M.
  • Montero-Marín, J.
  • Bohlmeijer, E. T.
  • Campos, D.
  • Cebolla, A.
  • Feliu-Soler, A.
Engaged Living (values clarity and committed action) is a main process of psychological flexibility as defined by Acceptance and Commitment Therapy. The Engaged Living Scale (ELS) was designed to measure it. The purpose of this study was to translate the ELS to Spanish and to examine the reliability and validity of its scores in a heterogeneous sample of 752 Spanish pilgrims of the Way of Saint James (pre-post analysis: n = 285). Confirmatory factor analyses were computed to study the structural validity of the ELS scores. In addition, network analyses were computed to examine convergent and discriminant validity. The included variables were engaged living, mindfulness facets, satisfaction with life, subjective happiness, affect, depression, anxiety, and perceived stress. Results showed that the Spanish version of the ELS is two-factorial (valued living [VL] and life fulfillment [LF]). The ELS scores showed good reliability. In addition, it was able to detect VL and LF changes after the Way underscoring its sensitivity to change. The network analyses indicated adequate convergent and discriminant validity of the ELS. Changes in satisfaction with life, life fulfillment, happiness, and valued living scores were most strongly associated with changes in perceived stress, affect, mindfulness facets, depression, and anxiety. In short, the Spanish version of the ELS appeared to be a reliable and valid instrument to assess the engaged response style in the current samples.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mindfulness-Based Program Plus Amygdala and Insula Retraining (MAIR) for the Treatment of Women with Fibromyalgia, a Pilot Randomized Controlled Trial

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Gasión, Virginia
  • Navarro-Gil, Mayte|||0000-0003-4842-0453
  • Morillo, Héctor|||0000-0002-9852-2776
  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Borràs, Xavier|||0000-0003-3972-1385
  • Tops, Mattie
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Garcia-Campayo, Javier|||0000-0002-3797-4218
  • Montero-Marín, Jesús|||0000-0001-5677-1662
  • Feliu-Soler, Albert|||0000-0003-2810-7670
The lack of highly effective treatments for fibromyalgia (FM) represents a great challenge for public health. The objective of this parallel, pilot randomized controlled trial (RCT) was two-fold: (1) to analyze the clinical effects of mindfulness plus amygdala and insula retraining (MAIR) compared to a structurally equivalent active control group of relaxation therapy (RT) in the treatment of FM; and (2) to evaluate its impact on immune-inflammatory markers and brain-derived neurotrophic factor (BDNF)in serum. A total of 41 FM patients were randomized into two study arms: MAIR (intervention group)and RT (active control group), both as add-ons of treatment as usual. MAIR demonstrated significantly greater reductions in functional impairment, anxiety, and depression, as well as higher improvements in mindfulness, and self-compassion at post-treatment and follow-up, with moderate to large effectsizes. Significant decreases in pain catastrophizing and psychological inflexibility and improvementsin clinical severity and health-related quality of life were found at follow-up, but not at post-treatment,showing large effect sizes. The number needed to treat was three based on the criteria of ≥50% Fibromyalgia Impact Questionnaire (FIQ) reduction post-treatment. Compared to RT, the MAIRshowed significant decreases in BDNF. No effect of MAIR was observed in immune-inflammatorybiomarkers (i.e., TNF-α, IL-6, IL-10, and hs-CRP). In conclusion, these results suggest that MAIR, as an adjuvant of treatment-as-usual (TAU), appears to be effective for the management of FM symptomsand for reducing BDNF levels in serum.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Social inequities in the impact of COVID-19 lockdown measures on the mental health of a large sample of the Colombian population (PSY-COVID study)

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Useche-Aldana, Bernardo
  • Ochoa, Pedro Pablo|||0000-0003-3035-8647
  • Rojas-Gualdrón, Diego Fernando|||0000-0002-2293-0431
  • Mateo Canedo, Corel|||0000-0002-0620-9257
  • Carmona Cervelló, Meritxell|||0000-0003-0907-9168
  • Crespo-Puig, Neus|||0000-0001-8036-6739
  • Selva Olid, Clara|||0000-0001-7390-9889
  • Muro Rodríguez, Anna|||0000-0002-1331-9921
  • Méndez Ulrich, Jorge Luis|||0000-0001-9718-0607
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
The identification of general population groups particularly vulnerable to the impact of COVID-19 lockdown measures on mental health and the development of healthcare policies are priority challenges in the current and future pandemics. This study aimed to identify the personal and social determinants of the impact of COVID-19 lockdown measures on mental health in a large sample of the Colombian population. In this cross-sectional study, an anonymous online survey was answered by 18,061 participants from the general population residing in Colombia during the first wave of the COVID-19 outbreak (from 20 May to 20 June 2020). The risk of depression, anxiety, and somatization disorders were measured using the Patient Health Questionnaire (PHQ-2), Generalized Anxiety Disorder Scale (GAD-2), and Somatic Symptom Questionnaire (SSQ-5), respectively. Overall, 35% of participants showed risk of depression, 29% of anxiety, and 31% of somatization. According to the analysis of social determinants of health, the most affected groups were people with low incomes, students, and young adults (18-29 years). Specifically, low-income young females were the most at-risk population group. These findings show how the lockdown measures affected the general population's mental health in Colombia and highlight some social risk factors in health.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Hernández-Negrín, Halbert
  • Borràs, Xavier|||0000-0003-3972-1385
  • Suso-Ribera, Carlos|||0000-0002-2655-1017
  • García Palacios, Azucena|||0000-0001-9250-8714
  • Muchart, Jordi
  • Munuera, Josep|||0000-0001-5154-1796
  • D'Amico, Francesco|||0000-0001-7995-826X
  • Maes, Michael|||0000-0002-2012-871X
  • Younger, Jarred W.
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Rozadilla-Sacanell, Antoni|||0000-0002-7555-189X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
There is evidence that low-dose naltrexone (LDN; <5.0 mg/day) reduces pain and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no randomised controlled trials with long-term follow-ups have been carried out. The INNOVA study will evaluate the add-on efficacy, safety, cost-utility and neurobiological effects of LDN for reducing pain in patients with FMS, with a 1-year follow-up. A single-site, prospective, randomised, double-blinded, placebo-controlled, parallel design phase III trial will be performed. Eligibility criteria include being adult, having a diagnosis of FMS and experiencing pain of 4 or higher on a 10-point numerical rating scale. Participants will be randomised to a LDN intervention group (4.5 mg/day) or to a placebo control group. Clinical assessments will be performed at baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3). The primary endpoint will be pain intensity. A sample size of 60 patients per study arm (120 in total), as calculated prior to recruitment for sufficient power, will be monitored between January 2022 and August 2024. Assessment will also include daily ecological momentary evaluations of FMS-related symptoms (eg, pain intensity, fatigue and sleep disturbance), and side effects via ecological momentary assessment through the Pain Monitor app during the first 3 months. Costs and quality-adjusted life years will be also calculated. Half of the participants in each arm will be scanned with MRI at T0 and T1 for changes in brain metabolites related to neuroinflammation and central sensitisation. Inflammatory biomarkers in serum will also be measured. This study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media and community engagement activities. .
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immune-inflammatory and hypothalamic-pituitary-adrenal axis biomarkers are altered in patients with non-specific low back pain, A systematic review

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Carmona Cervelló, Meritxell|||0000-0003-0907-9168
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Borràs, Xavier|||0000-0003-3972-1385
  • Grasa, Mar
  • Esteve, Montserrat|||0000-0003-2128-7859
  • Maes, Michael|||0000-0002-2012-871X
  • Edo Izquierdo, Sílvia|||0000-0002-6564-3475
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
  • Luciano, Juan Vicente|||0000-0003-0750-1599
, identifier CRD42020176153.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Over 40 years (1981-2023) assessing stigma with the Community Attitudes to Mental Illness (CAMI) scale, a systematic review of its psychometric properties

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Doval Dieguez, Eduardo|||0000-0001-8416-160X
  • Bernadàs, Albert
  • Angarita-Osorio, Natalia|||0000-0001-8925-2754
  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Evans-Lacko, Sara
  • Thornicroft, Graham
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Rubio-Valera, Maria|||0000-0003-2856-1697
The Community Attitudes to Mental Illness (CAMI) scale measures social stigma towards people with mental illness. Although it has been used worldwide, the psychometric properties of the CAMI have not been systematically reviewed. The main aim of this study was to systematically review the psychometric properties of the different versions of the CAMI more than 40 years after of its publication. A systematic search was conducted in MEDLINE, PsycINFO, Web of Science, and EMBASE from 1981 (year of publication) to 2023 (present). A double review was performed for eligibility, data extraction, and quality assessment. A total of 15 studies enrolling 10,841 participants were included. The most frequently reported factor structure comprises 3 or 4 factors. Overall, the internal consistency seems adequate for the global scale (α ≥ 0.80), except for CAMI-10 (α = 0.69). Internal consistency of the subscales are not supported, with authoritarianism being the weakest factor (α = 0.27 to 0.68). The stability over time of the total scale has been assessed in the CAMI-40, CAMI-BR, and CAMI-10 (r ≥ 0.39). Few studies have assessed the temporal stability of the CAMI subscales. Most of the correlations with potentially related measures are significant and in the expected direction. The 3 and 4 factor structure are the most widely reported in the different versions of the CAMI. Even though reliability and construct validity are acceptable, further item refinement by international consensus seems warranted more than 40 years after the original publication. PROSPERO identification number: CRD42018098956. The online version contains supplementary material available at 10.1186/s13643-023-02230-4.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dimensionality and reliability of the online version of the Patient Health Questionnaire-4 (PHQ-4) in a large Colombian sample, Results from the PSY-COVID study

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Gomez-Acosta, Andrés|||0000-0002-7932-0466
  • Castro Muñoz, John Alexander|||0000-0002-4881-6071
  • Rojas, Yonatan Ferney
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
The Patient Health Questionnaire-4 (PHQ-4) is an ultra-brief screening instrument to measure depressive and anxiety symptoms. This study evaluated the dimensionality and reliability of the online version of the PHQ-4 in a large sample of the general population in Colombia. Data were collected during the first phase of lockdown measures occasioned by the COVID-19 pandemic. A total of 18,061 adult participants completed the online version of the PHQ-4. The characteristics of the items and subscales were explored. Dimensionality was examined using confirmatory factor analysis (CFA), including an examination of invariance (configural, metric, and scalar) across socio-demographic characteristics. Reliability indices were computed and known-groups validity was addressed by estimating associations between PHQ-4 scores and socio-demographic characteristics. The CFA showed significantly adequate fit indices for the expected two-factor structure, being invariant across gender, age, income level, education level, and region. Internal consistency was satisfactory for the PHQ-2 (α =.83), the GAD-2 (α =.79), and the PHQ-4 (α =.86). Higher scores on depressive (PHQ-2), anxiety (GAD-2), and psychological distress (PHQ-4) symptoms in females and young people, and those respondents with lower income, unemployed, and lower level of education were observed. The findings indicate that the PHQ-4 is a reliable scale for depressive and anxiety symptoms among adult Colombian people, being recommendable this tool for online surveys.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Economic evaluation of videoconference group acceptance and commitment therapy and behavioral activation therapy for depression versus usual care among adults with chronic low back pain plus comorbid depressive symptoms

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • D'Amico, Francesco|||0000-0001-7995-826X
  • Cardeñosa, Eugenia|||0000-0002-9735-2269
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Edo Izquierdo, Sílvia|||0000-0002-6564-3475
  • Borràs, Xavier|||0000-0003-3972-1385
  • McCracken, Lance M.|||0000-0002-9734-0153
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
  • Luciano, Juan Vicente|||0000-0003-0750-1599
Chronic pain and depression are frequently comorbid conditions associated with significant healthcare and social costs.This study examined the cost-utility and cost-effectiveness of videoconference-based group forms of Acceptance and Commitment Therapy (ACT) and Behavioral Activation Therapy for Depression (BATD), as a complement to treatment-as-usual (TAU), for patients with chronic low back pain (CLBP) plus depressive symptoms, compared to TAU alone. A trial-based economic evaluation (n = 234) was conducted from a governmental and healthcare perspective with a time horizon of 12 months. Primary outcomes were the Brief Pain Inventory-Interference Scale (BPI-IS) and Quality Adjusted Life Year (QALY). Compared to TAU, ACT achieved a significant reduction in total costs (d = 0.47), and BATD achieved significant reductions in indirect (d = 0.61) and total costs (d = 0.63). Significant improvements in BPI-IS (d = 0.73 and d = 0.66, respectively) and QALY scores (d = 0.46 and d = 0.28, respectively) were found in ACT and BATD compared to TAU. No significant differences in costs and outcomes were found between ACT and BATD. In the intention-to-treat analyses, from the governmental and healthcare perspective, no significant differences in cost reduction and incremental effects were identified in the comparison between ACT, BATD, and TAU. However, in the complete case analysis, significant incremental effects of ACT (∆BPI-IS = -1.57 and -1.39, respectively) and BATD (∆BPI-IS = -1.08 and -1.04, respectively) compared with TAU were observed. In the per-protocol analysis, only the significant incremental effects of ACT (∆BPI-IS = -1.68 and -1.43, respectively) compared to TAU were detected. In conclusion, ACT and BATD might be efficient options in the management of CLBP plus comorbid depression symptoms as compared to usual care. However, no clear difference was found in the comparison between the two active therapies regarding cost-effectiveness or cost-utility. PERSPECTIVE: The economic evaluation of psychological therapies for the management of complex conditions is crucial as can be used in decision-making and resource allocation. This study provides evidence that videoconference group-based forms of ACT and BATD are more effective and involve a greater reduction in costs than usual care in the management of CLBP plus comorbid depressive symptoms. Both psychological therapies seem to offer good value for money to the Spanish national health service and the government.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effectiveness of a Multicomponent Treatment Based on Pain Neuroscience Education, Therapeutic Exercise, Cognitive Behavioral Therapy, and Mindfulness in Patients With Fibromyalgia (FIBROWALK Study), A Randomized Controlled Trial

  • Serrat López, Mayte|||0000-0002-5591-9407
  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Almirall, Míriam|||0000-0002-4874-8013
  • Musté, Marta|||0000-0002-0748-1121
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Méndez Ulrich, Jorge Luis|||0000-0001-9718-0607
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
  • Luciano, Juan Vicente|||0000-0003-0750-1599
Objective. The purpose of this study was to evaluate the effectiveness of a 12-week multicomponent treatment based on pain neuroscience education, therapeutic exercise, cognitive behavioral therapy, and mindfulness-in addition to treatment as usual-compared with treatment as usual only in patients with fibromyalgia. Methods. This randomized controlled trial involved a total of 272 patients who were randomly assigned to either multicomponent treatment (n = 135) or treatment as usual (n = 137). The multicomponent treatment (2-hour weekly sessions) was delivered in groups of 20 participants. Treatment as usual was mainly based on pharmacological treatment according to the predominant symptoms. Data on functional impairment using the Revised Fibromyalgia Impact Questionnaire as the primary outcome were collected as were data for pain, fatigue, kinesiophobia, physical function, anxiety, and depressive symptoms (secondary outcomes) at baseline, 12 weeks, and, for the multicomponent group only, 6 and 9 months. An intention-to-treat approach was used to analyze between-group differences. Baseline differences between responders (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Psychometric examination of the Multidimensional Psychological Flexibility Inventory Short Form (MPFI-24) and the Psy-Flex Spanish versions in individuals with chronic pain

  • Navarrete Hidalgo, Jaime|||0000-0002-9482-4822
  • Rodríguez Freire, Carla|||0009-0006-6728-5778
  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Martínez-Rubio, David|||0000-0002-9346-3869
  • McCracken, Lance M.|||0000-0002-9734-0153
  • Gallego, Ana|||0000-0002-8060-2495
  • Sundström, Felicia T.A.|||0000-0002-7032-1614
  • Serrat López, Mayte|||0000-0002-5591-9407
  • Alonso, Jordi|||0000-0001-8627-9636
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Nieto Luna, Rubén|||0000-0002-8759-319X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
BACKGROUND: Acceptance and Commitment Therapy (ACT) has been found to be beneficial for individuals dealing with chronic pain. The theoretical mechanisms of change proposed by ACT are based on the Hexaflex model. To comprehensively reflect this model, the Multidimensional Psychological Flexibility Inventory (MPFI) and Psy-Flex have been developed. The study aimed to adapt the MPFI-24 and the Psy-Flex for Spanish-speaking populations with chronic pain and to examine their dimensionality, internal consistency, convergent validity and incremental validity. METHODS: This cross-sectional study involved 309 Spanish-speaking adults with chronic pain who completed an online survey. The majority of the participants were women (88.3%). The ages ranged from 18 to 79 years. RESULTS: Factor analysis showed that the Spanish version of the MPFI-24 has 12 factors, consisting of six flexibility and six inflexibility factors, similar to the original version, but lacking second-order general factors. The Psy-Flex demonstrated a single-factor structure, maintaining the general factor of psychological flexibility seen in the original version. The MPFI-24 showed good internal consistency and adequate convergent validity, with the exception of the Acceptance and Experiential Avoidance subscales. The Psy-Flex showed good internal consistency and convergent validity. Notably, both the MPFI-24 and Psy-Flex scores significantly explained additional variance in psychological distress beyond other ACT-related measures of Hexaflex processes; however, only the Psy-Flex explained pain interference. CONCLUSIONS: The Spanish adaptations of the MPFI-24 and Psy-Flex are valid and reliable instruments for assessing the Hexaflex model processes in Spanish-speaking adults with chronic pain. SIGNIFICANCE STATEMENT: Practitioners and researchers in chronic pain will find the Spanish versions of the MPFI-24 and the Psy-Flex here, along with recommendations for their use and scoring based on a robust psychometric rationale. It should be noted that these measures surpass the Chronic Pain Acceptance Questionnaire (CPAQ) and the Psychological Inflexibility in Pain Scale (PIPS), which are considered gold standards in chronic pain assessment.